Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium

Investigational New Drugs

Volumn 26, Issue 2, 2008, Pages 151-158

  Hutson, Thomas E ^a,b,c   Vukelja, Svetislava ^a,c   Atienza, Daniel ^a,d   Awasthi, Sanjay ^a,c   Delaune, Robert ^a,e   Deutsch, Margaret ^a,c   Dien, Philip Y ^a,e   Gregory, Thomas F ^a,c   Kolodziej, Michael J ^a,f   Muscato, Joseph J ^a,g   Raju, Robert N ^a,h   Ruxer Jr , Robert L ^a,c   Mull, Stephanie ^a   Ilegbodu, Des ^a   Hood, Karen ⁱ   Nicol, Steven ⁱ   Berry, William ^a,j  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c TEXAS ONCOLOGY   (United States)

^d Virginia Oncology Associates   (United States)

^e Minnesota Oncology and Hematology Professional Association   (United States)

^f New York Oncology Hematology   (United States)

^g Missouri Cancer Associates   (United States)

^h Dayton Oncology and Hematology   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j Rex Hematology/Oncology Associates   (United States)

more..

Author keywords

Cisplatin; Gemcitabine; Pemetrexed; Transitional cell carcinoma; Urothelium

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DIFLUNISAL; FOLIC ACID; GEMCITABINE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEMETREXED; PIROXICAM;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ALOPECIA; ANURIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSCIOUSNESS; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; LEUKOPENIA; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; URINARY TRACT CANCER; UROTHELIUM; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLIC ACID; GLUTAMATES; GUANINE; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 40549114638     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9111-2     Document Type: Article

References (21)

1. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608
3. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogue M, Bastus R, Climent MA, de la Cruz JJ, Albanell J, Banus JM, Gallardo E, Diaz-Rubio E, Cortes-Funes H, Baselga J (2000) Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18:3247-3255
4. Pectasides D, Glotsos J, Bountouroglou N, Kouloubinis A, Mitakidis N, Karvounis N, Ziras N, Athanassiou A (2002) Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13:243-250
5. Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, Mavroudis D, Georgoulias V (2006) Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Oncol 17:1687-1692
6. Cisplatin plus gemcitabine with or without paclitaxel in treating patients with stage iv urinary tract cancer. http://www.clinicaltrials.gov/ct/ show/NCT00022191.
7. Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK (2006) Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24:4840-4847
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 15:2636-2644
9. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24:3451-3457
10. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA Jr, Ettinger DS (2004) Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 10:5439-5446
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
12. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
13. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123
14. Schultz RM, Andis SL, Bewley JR, Chen VJ, Habeck LL, Mendelsohn LG, Patel VF, Rutherford PG, Self TD, Shih C, Theobald KS, Worzalla JF, Houghton JF (1996) Anti-tumor activity of the multi-targeted antifolate LY231514 (Abstract). Proc Am Assoc Cancer Res 37:380(abstr 2597)
15. Paz-Ares L, Tabernero J, Moyano A (1998) Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a Phase II trial. Ann Oncol 9(suppl 4):292
16. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF (2007) Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drug 25:265-270
17. Tonkinson JL, Worzolla JF, Teng CH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671-3676
18. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J (2000) Phase I and pharmacologic study of sequences of gemcitabine and multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757
19. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer 92:595-600
20. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K (2000) Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA ™) and cisplatin: a multicenter phase II trial. Ann Oncol 11:435-440
21. Bolling C, Lubbing C, Graefe T, Mack S, Von Schee J, Muller-Hagen S, Blatter J, Depenbrock H, Ohnmacht U, Hanauske AR (2004) Pemetrexed/gemcitabine/ cisplatin: a phase I trial in patients with solid tumors (Abstract). Proc Am Soc Clin Oncol 22:(14S, Abstr 3096)